Literature DB >> 10066655

Plasma-soluble CD30 in childhood tuberculosis: effects of disease severity, nutritional status, and vitamin A therapy.

W A Hanekom1, G D Hussey, E J Hughes, S Potgieter, R Yogev, I J Check.   

Abstract

Plasma-soluble CD30 (sCD30) is the result of proteolytic splicing from the membrane-bound form of CD30, a putative marker of type 2 cytokine-producing cells. We measured sCD30 levels in children with tuberculosis, a disease characterized by prominent type 1 lymphocyte cytokine responses. We postulated that disease severity and nutritional status would alter cytokine responses and therefore sCD30 levels. Samples from South African children enrolled prospectively at the time of diagnosis of tuberculosis were analyzed. (Patients were originally enrolled in a randomized, double-blind placebo-controlled study of the effects of oral vitamin A supplementation on prognosis of tuberculosis.) Plasma samples collected at the time of diagnosis and 6 and 12 weeks later (during antituberculosis therapy) were analyzed. sCD30 levels were measured by enzyme immunoassay. The 91 children included in the study demonstrated high levels of sCD30 at diagnosis (median, 98 U/liter; range, 11 to 1,569 U/liter). Although there was a trend toward higher sCD30 levels in more severe disease (e.g., culture-positive disease or miliary disease), this was not statistically significant. Significantly higher sCD30 levels were demonstrated in the presence of nutritional compromise: the sCD30 level was higher in patients with a weight below the third percentile for age, in those with clinical signs of kwashiorkor, and in those with a low hemoglobin content. There was minimal change in the sCD30 level after 12 weeks of therapy, even though patients improved clinically. However, changes in sCD30 after 12 weeks differed significantly when 46 patients (51%) who received vitamin A were compared with those who had received a placebo. Vitamin A-supplemented children demonstrated a mean (+/- standard error of the mean) decrease in sCD30 by a factor of 0.99 +/- 0.02 over 12 weeks, whereas a factor increase of 1.05 +/- 0.02 was demonstrated in the placebo group (P = 0.02). We conclude that children with tuberculosis had high sCD30 levels, which may reflect the presence of a type 2 cytokine response. Nutritional compromise was associated with higher sCD30 levels. Vitamin A therapy resulted in modulation of sCD30 levels over time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10066655      PMCID: PMC95688          DOI: 10.1128/CDLI.6.2.204-208.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  A randomized, controlled trial of vitamin A in children with severe measles.

Authors:  G D Hussey; M Klein
Journal:  N Engl J Med       Date:  1990-07-19       Impact factor: 91.245

Review 2.  CD30 and type 2 T helper (Th2) responses.

Authors:  S Romagnani; G Del Prete; E Maggi; M Chilosi; F Caligaris-Cappio; G Pizzolo
Journal:  J Leukoc Biol       Date:  1995-05       Impact factor: 4.962

Review 3.  CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

Authors:  B Falini; S Pileri; G Pizzolo; H Dürkop; L Flenghi; F Stirpe; M F Martelli; H Stein
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

4.  Regulation of cytokine patterns in leprosy.

Authors:  P A Sieling; R L Modlin
Journal:  Ann N Y Acad Sci       Date:  1994-08-15       Impact factor: 5.691

5.  Vitamin A status and therapy in childhood pulmonary tuberculosis.

Authors:  W A Hanekom; S Potgieter; E J Hughes; H Malan; G Kessow; G D Hussey
Journal:  J Pediatr       Date:  1997-12       Impact factor: 4.406

6.  Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls.

Authors:  F O Sánchez; J I Rodríguez; G Agudelo; L F García
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

7.  High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS.

Authors:  G Pizzolo; F Vinante; L Morosato; G Nadali; M Chilosi; G Gandini; A Sinicco; R Raiteri; G Semenzato; H Stein
Journal:  AIDS       Date:  1994-06       Impact factor: 4.177

8.  Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens.

Authors:  H M Surcel; M Troye-Blomberg; S Paulie; G Andersson; C Moreno; G Pasvol; J Ivanyi
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

Review 9.  Vitamin A, immunity, and infection.

Authors:  R D Semba
Journal:  Clin Infect Dis       Date:  1994-09       Impact factor: 9.079

10.  Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines.

Authors:  G Del Prete; M De Carli; F Almerigogna; C K Daniel; M M D'Elios; G Zancuoghi; F Vinante; G Pizzolo; S Romagnani
Journal:  FASEB J       Date:  1995-01       Impact factor: 5.191

View more
  3 in total

Review 1.  Childhood tuberculosis and malnutrition.

Authors:  Devan Jaganath; Ezekiel Mupere
Journal:  J Infect Dis       Date:  2012-10-02       Impact factor: 5.226

2.  Increased levels of BAFF and APRIL related to human active pulmonary tuberculosis.

Authors:  Kai Liu; Yan Zhang; Shizong Hu; Yang Yu; Qianting Yang; Dongdong Jin; Xinchun Chen; Qi Jin; Haiying Liu
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

3.  A pilot study assessing the impact of a fortified supplementary food on the health and well-being of crèche children and adult TB patients in South Africa.

Authors:  Michael Rudolph; Florian Kroll; Moira Beery; Edmore Marinda; Jean-Francois Sobiecki; Geoffrey Douglas; Gary Orr
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.